SCHEMBL490478

SCHEMBL490478

CC(C)(C)OC(=O)N[C@@H](CC=Cc1ccc(B2OC(C)(C)C(C)(C)O2)c(Cl)c1)C(=O)OC1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 6/20 0.42
AAK1 Q2M2I8 3/20 0.36
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
PKM P14618 1/20 0.34
HPGD P15428 1/20 0.34
ALOX12 P18054 1/20 0.34
CTSS P25774 1/20 0.31
CTSK P43235 1/20 0.31
KLK7 P49862 2/20 0.31
KLK5 Q9Y337 2/20 0.31
GLA P06280 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
USP30 Q70CQ3 1/20 0.31
CTSL P07711 1/20 0.31
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490475 1.00 CACNA1B (0.42) CACNA1BAAK1KDM4EALDH1A1GAA
SCHEMBL490796 0.87 CACNA1B (0.44) CACNA1BAAK1CTSSCTSKKLK7
SCHEMBL490471 0.87 CACNA1B (0.44) CACNA1BAAK1CTSSCTSKKLK7
SCHEMBL490799 0.87 CACNA1B (0.44) CACNA1BAAK1CTSSCTSKKLK7
SCHEMBL490390 0.87 CACNA1B (0.44) CACNA1BAAK1CTSSCTSKKLK7
SCHEMBL490387 0.87 CACNA1B (0.44) CACNA1BAAK1CTSSCTSKKLK7
SCHEMBL1147484 0.86 CACNA1B (0.44) CACNA1BAAK1CTSSCTSKKLK7
SCHEMBL1147480 0.86 CACNA1B (0.44) CACNA1BAAK1CTSSCTSKKLK7
SCHEMBL1147714 0.83 CACNA1B (0.41) CACNA1BAAK1KDM4EALDH1A1GAA
SCHEMBL1147709 0.83 CACNA1B (0.41) CACNA1BAAK1KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106091-B2 Inhibitors of IKK-beta serine-threonine protein kinase CHROMA THERAPEUTICS LTD. (GB) 2012-01-31 US disclosed
EP-2086956-B1 INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE CHROMA THERAPEUTICS LTD (GB) 2011-09-14 EP disclosed
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase CHROMA THERAPEUTICS LTD. (GB) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase IKBKB, IKBKE, CHUK CACNA1B 2344/4885AAK1 1469/4885KDM4E 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.